A team of researchers at King's College London has identified a previously overlooked mechanism of brain cell death that appears to play a central role in Alzheimer's disease and frontotemporal dementia. The process, known as karyoptosis, involves the progressive shrinking and eventual disintegration of the cell nucleus after toxic proteins accumulate inside neurons. The findings, published in Nature Communications, could reshape the scientific understanding of how neurodegeneration occurs and open new avenues for treatment.
For decades, scientists have known that toxic protein buildups, including amyloid beta plaques and tau tangles, are hallmarks of Alzheimer's disease and frontotemporal dementia. However, the precise mechanism by which these proteins kill brain cells has remained elusive. The King's College London team, led by Dr. Rebecca Casterton of the UK Dementia Research Institute and Dr. Manolis Fanto from the Institute of Psychiatry, Psychology and Neuroscience, used computational algorithms to analyze approximately 3,000 brain cells from 28 patients diagnosed with either frontotemporal dementia or end-stage Alzheimer's disease.
The analysis revealed that 35 percent of cells in the frontal cortex of Alzheimer's patients showed clear markers of karyoptosis, compared with only 15 percent in healthy aged control subjects. At the molecular level, the researchers identified a critical interaction between p38 MAP kinase and the LaminB1 protein that destabilizes the outer membrane of the cell nucleus, triggering its breakdown. This kinase-protein interaction appears to act as a molecular switch that, once activated by toxic protein accumulation, sets the cell on an irreversible path toward death.
Crucially, when the research team targeted these molecular switches in laboratory experiments using rat neurons, they observed a significant reduction in karyoptosis markers. This suggests that interrupting the p38 MAP kinase-LaminB1 pathway could potentially slow or even prevent the progressive neuronal loss that characterizes both Alzheimer's disease and frontotemporal dementia. Dr. Casterton stated that the team has begun mapping out how karyoptosis works and expressed enthusiasm about future breakthroughs this research may drive.
The study was funded by Alzheimer's Research UK, the Biotechnology and Biological Sciences Research Council, the UK Medical Research Council, and the UK Dementia Research Institute. Experts in the field have described the discovery as a significant step forward, noting that existing treatments for Alzheimer's have largely focused on removing toxic protein plaques rather than addressing the downstream cell death processes directly.
Alzheimer's disease affects an estimated 55 million people worldwide, with that number projected to nearly triple by 2050 according to the World Health Organization. Frontotemporal dementia, while less common, is a leading cause of early-onset dementia in people under 65. The identification of karyoptosis as a shared mechanism across both conditions raises the possibility that a single therapeutic approach could benefit patients suffering from multiple forms of neurodegeneration.
Future research will focus on selectively targeting the p38 MAP kinase-LaminB1 interaction to develop viable treatment candidates for human clinical trials. The team at King's College London plans to collaborate with pharmaceutical partners to explore whether existing kinase inhibitors could be repurposed to combat karyoptosis in the human brain, potentially offering hope to millions of dementia patients and their families worldwide.
Comments